Sander Flaum, Flaum Navigators

Congress puts big price tag on innovation in pharma

September 7, 2018

1:00 pm

It has become expensive to develop drugs — especially for specific mutations and small patient populations. But instead of helping pharma adapt, Congress is making innovation more costly.

Focus turns to future after Right to Try Act passes

Sander Flaum, Flaum Navigators

August 3, 2018

5:00 pm

Congress has finally passed the Right to Try Act, but does it go far enough?

Drugs’ value to patients eclipsed by price tags

Sander Flaum, Flaum Navigators

May 4, 2018

5:00 pm

Like other sectors, pharma is experiencing upheavals no one predicted, and as a result, drugs are being reviled for their price tags, rather than praised for their value.

Will PBMs take heat for high drug prices?

Sander Flaum, Flaum Navigators

March 29, 2018

2:00 pm

PBMs began by providing a huge service to payers, but in recent years, they’ve begun to suck revenue from pharma manufacturers. Will they take some heat for high drug prices?

Can a nonprofit make generics great again?

Sander Flaum, Flaum Navigators

March 7, 2018

12:00 pm

Acquisitions that were applauded a few years ago, such as Teva’s purchase of Allergan’s generic business, now look like lemons.

Did Congress just kill the Orphan Drug Act?

Sander Flaum, Flaum Navigators

February 13, 2018

12:00 pm

By allowing companies to claim a 50% tax credit for qualified clinical testing expenses, developing drugs for rare diseases became economically feasible for the first time.

We Save Lives While Our Critics Complain

Sander Flaum, Flaum Navigators

January 25, 2018

12:00 pm

In his first press conference as president-elect, Donald Trump insisted pharma was “getting away with murder” due to expensive drug prices.

Gottlieb Eyes Prices, Not Lives

Sander Flaum, Flaum Navigators

December 14, 2017

12:00 pm

It turns out the real goal is going after Washington’s favorite whipping boy — high drug prices.

Who’s Getting Rich in Healthcare?

Sander Flaum, Flaum Navigators

October 30, 2017

11:00 am

Do you recall what President Trump tweeted right after Merck’s Kenneth Frazier resigned from his American Manufacturing Council?

AI Drug Design Could Save Lives

Sander Flaum, Flaum Navigators

October 3, 2017

11:00 am

AI complements what we in pharma have always done best — respond to medical needs quickly and find solutions.

From Our Partners

Partner Content

HCP engagement in 2022 — The HLD HCP Communications Report

Healthlink Dimensions’ 2022 Communications Report — your guide for provider-based insights into HCP marketing outreach as COVID continues to reshape the industry.

Partner Content

Health musings and predictions as we close out 2021

Kim Johnson, Global CEO of Ogilvy Health, sits down with Steve Madden to share her insights on industry developments and challenges over the past year, as well as some thoughts about the unique opportunities for growth in the coming year.

Partner Content

Are more vaccine options the answer for a pandemic-weary public?

For the vaccine hesitant who are still contemplating their first, second or booster doses — or are reluctant to vaccinate their children — perhaps more options would help spur them beyond their hesitations.

Partner Content

Using data signals to understand patient needs

Patients' needs extend beyond their condition — there are multidimensional people behind each diagnosis searching for answers about their interests, hobbies, emotions, lifestyle choices, and more. Now, more than ever, it’s important to find ways to understand consumers as a whole. We can better reach them — and support them — when we do.

HAYMARKET MARKETING COMMUNICATIONS:

HAYMARKET MARKETING COMMUNICATIONS:

Quick Links

Congress puts big price tag on innovation in pharma

Focus turns to future after Right to Try Act passes

Drugs’ value to patients eclipsed by price tags

Will PBMs take heat for high drug prices?

Can a nonprofit make generics great again?

Did Congress just kill the Orphan Drug Act?

We Save Lives While Our Critics Complain

Gottlieb Eyes Prices, Not Lives

Who’s Getting Rich in Healthcare?

AI Drug Design Could Save Lives

Places to Be 2021

From Our Partners

Partner Content

HCP engagement in 2022 — The HLD HCP Communications Report

Partner Content

Health musings and predictions as we close out 2021

Partner Content

Are more vaccine options the answer for a pandemic-weary public?

Partner Content

Using data signals to understand patient needs

Thank you for accessing MM+M.